Benefits of Repeated SARS-CoV-2 Vaccination and Virus-induced Cross-neutralization Potential in Immunocompromised Transplant Patients and Healthy Individuals
Potentially protective SARS-CoV-2 neutralization is reliably induced in immunocompromised individuals by prior attenuation of immunosuppression. First-generation vaccines protect against various SARS-CoV-2 variants in immunocompetent individuals, with effective cross-neutralization demonstrated up to the Delta variant but largely absent for later Omicron variants. Continuous vaccine updates are necessary to address emerging SARS-CoV-2 variants.
Authors
- Christian Mittelholzer (ORCID: https://orcid.org/0000-0003-4353-3555)
- Lorena Urda (ORCID: https://orcid.org/0009-0007-4122-515X)
- Martin J. Lett (ORCID: https://orcid.org/0000-0002-7230-9264)
- Enja Kipfer (ORCID: https://orcid.org/0000-0001-5870-6784)
- David Hauser (ORCID: https://orcid.org/0000-0001-9950-365X)
- Thomas Klimkait (ORCID: https://orcid.org/0000-0003-4945-6511)
- Christopher Lang (ORCID: https://orcid.org/0000-0002-6052-6835)
- Fabian Otte (ORCID: https://orcid.org/0000-0003-0572-617X)
- Yuepeng Zhang (ORCID: https://orcid.org/0009-0009-7923-2173)
- Wilfried Klimkait
- Christiane Schebitz
- Roman‐Ulrich Müller
Institutions
- University of Cologne (DE)
- University of Basel (CH)
- Nierenzentrum Heidelberg (DE)
- Praxis für Humangenetik (DE)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1093/ofid/ofae527
- Citations
- 1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.39